US Bancorp’s Palvella Therapeutics PVLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.6K | Sell |
17
-18
| -51% | -$2.19K | ﹤0.01% | 3814 |
|
|
2026
Q1 | $4.36K | Sell |
35
-300
| -90% | -$31.3K | ﹤0.01% | 3613 |
|
|
2025
Q4 | $35.1K | Buy |
335
+19
| +6% | +$1.62K | ﹤0.01% | 2845 |
|
|
2025
Q3 | $19.8K | Buy |
+316
| New | +$14.1K | ﹤0.01% | 3072 |
|
|
2025
Q1 | – | Sell |
-138
| Closed | -$1.66K | – | 4391 |
|
|
2024
Q4 | $1.66K | Hold |
138
| – | – | ﹤0.01% | 3889 |
|
|
2024
Q3 | $2.29K | Sell |
138
-20
| -13% | -$292 | ﹤0.01% | 3756 |
|
|
2024
Q2 | $1.55K | Buy |
158
+29
| +22% | +$327 | ﹤0.01% | 3755 |
|
|
2024
Q1 | $1.88K | Hold |
129
| – | – | ﹤0.01% | 3737 |
|
|
2023
Q4 | $1.87K | Hold |
129
| – | – | ﹤0.01% | 3715 |
|
|
2023
Q3 | $3.06K | Hold |
129
| – | – | ﹤0.01% | 3569 |
|
|
2023
Q2 | $1.7K | Hold |
129
| – | – | ﹤0.01% | 3722 |
|
|
2023
Q1 | $10K | Hold |
129
| – | – | ﹤0.01% | 3281 |
|
|
2022
Q4 | $10.7K | Hold |
129
| – | – | ﹤0.01% | 3277 |
|
|
2022
Q3 | $12K | Hold |
129
| – | – | ﹤0.01% | 3319 |
|
|
2022
Q2 | $19K | Hold |
129
| – | – | ﹤0.01% | 3096 |
|
|
2022
Q1 | $31K | Hold |
129
| – | – | ﹤0.01% | 2846 |
|
|
2021
Q4 | $39K | Hold |
129
| – | – | ﹤0.01% | 2779 |
|
|
2021
Q3 | $53K | Hold |
129
| – | – | ﹤0.01% | 2624 |
|
|
2021
Q2 | $39K | Hold |
129
| – | – | ﹤0.01% | 2792 |
|
|
2021
Q1 | $26K | Hold |
129
| – | – | ﹤0.01% | 2909 |
|
|
2020
Q4 | $26K | Hold |
129
| – | – | ﹤0.01% | 2799 |
|
|
2020
Q3 | $21K | Hold |
129
| – | – | ﹤0.01% | 2804 |
|
|
2020
Q2 | $32K | Hold |
129
| – | – | ﹤0.01% | 2610 |
|
|
2020
Q1 | $23K | Hold |
129
| – | – | ﹤0.01% | 2695 |
|
|
2019
Q4 | $37K | Hold |
129
| – | – | ﹤0.01% | 2614 |
|
|
2019
Q3 | $35K | Hold |
129
| – | – | ﹤0.01% | 2625 |
|
|
2019
Q2 | $48K | Hold |
129
| – | – | ﹤0.01% | 2546 |
|
|
2019
Q1 | $34K | Hold |
129
| – | – | ﹤0.01% | 2661 |
|
|
2018
Q4 | $27K | Hold |
129
| – | – | ﹤0.01% | 2705 |
|
|
2018
Q3 | $58K | Hold |
129
| – | – | ﹤0.01% | 2488 |
|
|
2018
Q2 | $52K | Hold |
129
| – | – | ﹤0.01% | 2568 |
|
|
2018
Q1 | $70K | Hold |
129
| – | – | ﹤0.01% | 2420 |
|
|
2017
Q4 | $78K | Hold |
129
| – | – | ﹤0.01% | 2379 |
|
|
2017
Q3 | $59K | Buy |
+129
| New | +$55.1K | ﹤0.01% | 2492 |
|
Other funds holding PVLA
SCM
FLSM
FLAM
BI
FCM
US Bancorp's PVLA Position: Q2 2026 in Review
US Bancorp reduced its Palvella Therapeutics (PVLA) stake by 51% in Q2 2026, selling an estimated $2.19K and leaving 17 shares worth $2.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3814.
US Bancorp first reported a position in PVLA in Q3 2017 and has held it in 34 quarters since. The position peaked at $78K in Q4 2017. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.
- US Bancorp held 17 shares of Palvella Therapeutics worth $2.6K as of Q2 2026.
- US Bancorp sold 18 Palvella Therapeutics shares in Q2 2026, an estimated $2.19K.
- Palvella Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3814 holding.
- US Bancorp first reported a position in Palvella Therapeutics in Q3 2017 and has held it in 34 quarters since.
- US Bancorp's Palvella Therapeutics position peaked at $78K in Q4 2017.
- 197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.
Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.